We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Extends Review of Merck’s Neuromuscular Reversal Agent
FDA Extends Review of Merck’s Neuromuscular Reversal Agent
March 22, 2013
The FDA has informed Merck it needs an additional three months to review its NDA for sugammadex sodium injection, a first-in-class neuromuscular reversal agent, the drug giant said.